688366.SHG Shanghai Haohai Biological Tech Co
- Market cap
- CNY 6.74B
- P/E
- 45.6x
- P/B
- 1.25x
- ROE
- 4.6%
- Dividend yield
- 3.39%
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is 688366.SHG undervalued?
Graham number688366.SHG trades 59.4% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Shanghai Haohai Biological Tech Co fundamental analysis
No fundamental analysis for Shanghai Haohai Biological Tech Co yet.
Shanghai Haohai Biological Tech Co stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Shanghai Haohai Biological Tech Co
Shanghai Haohai Biological Technology Co., Ltd. engages in the research, development, manufacture, and sale of biomedical materials in Mainland China, Europe, the United States, and internationally. The company offers ophthalmic implants, assistive devices, and medical devices; medical optical instruments, including intraocular lenses, endoscopic equipment, ophthalmic surgical instruments, and other ophthalmic medical products; hyaluronic acid and chitosan; and electronic in…
Full company profileShanghai Haohai Biological Tech Co financial statements
Shanghai Haohai Biological Tech Co annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 851M | 1.34B | 1.55B | 1.60B | 1.32B | 1.75B | 2.10B | 2.63B | 2.68B | 2.47B |
| Gross Profit | 710M | 1.06B | 1.21B | 1.23B | 990M | 1.26B | 1.45B | 1.85B | 1.84B | 1.71B |
| Operating Income | 284M | 366M | 369M | 291M | 79.7M | 176M | 156M | 368M | 348M | 220M |
| EBITDA | 401M | 531M | 610M | 536M | 375M | 523M | 422M | 689M | 661M | 417M |
| Net Income | 305M | 372M | 415M | 371M | 230M | 352M | 180M | 416M | 420M | 251M |
| EPS | 0.97 | 1.19 | 1.32 | 1.16 | 0.66 | 1.02 | 0.53 | 1.75 | 1.80 | 1.08 |
| Balance Sheet | ||||||||||
| Total Assets | 3.69B | 4.08B | 4.44B | 6.15B | 6.30B | 6.95B | 6.89B | 7.11B | 7.12B | 6.72B |
| Total Liabilities | 708M | 709M | 601M | 499M | 564M | 890M | 990M | 1.09B | 1.20B | 1.12B |
| Shareholders' Equity | 2.90B | 3.20B | 3.61B | 5.45B | 5.49B | 5.71B | 5.51B | 5.65B | 5.58B | 5.42B |
| Cash & Short-term Investments | 2.01B | 1.80B | 1.44B | 3.22B | 3.11B | 2.91B | 2.54B | 2.75B | 2.72B | 2.52B |
| Total Debt | 26.7M | 37.5M | 36.7M | 49.7M | 108M | 106M | 118M | 408M | 448M | 398M |
| Cash Flow | ||||||||||
| Operating Cash Flow | 254M | 343M | 391M | 349M | 262M | 342M | 231M | 634M | 649M | 491M |
| Capital Expenditure | 75.7M | 135M | 152M | 399M | 196M | 272M | 317M | 267M | 365M | 187M |
| Free Cash Flow | 179M | 208M | 239M | -50.4M | 66.2M | 70.2M | -85.9M | 367M | 283M | 304M |
| Ratios | ||||||||||
| ROE | 10.5% | 11.6% | 11.5% | 6.8% | 4.2% | 6.2% | 3.3% | 7.4% | 7.5% | 4.6% |
| ROA | 8.3% | 9.1% | 9.3% | 6.0% | 3.7% | 5.1% | 2.6% | 5.9% | 5.9% | 3.7% |
| Net Profit Margin | 35.8% | 27.7% | 26.8% | 23.2% | 17.4% | 20.1% | 8.6% | 15.8% | 15.7% | 10.1% |
| Debt to Equity | 0.01x | 0.01x | 0.01x | 0.01x | 0.02x | 0.02x | 0.02x | 0.07x | 0.08x | 0.07x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Shanghai Haohai Biological Tech Co dividends
- Dividend yield
- 3.39%
- Forward dividend
- 0.85 CNY
- Payout ratio
- 91.1%
- Ex-dividend date
- Sep 18, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 229M | 0.98 | 91.1% |
| 2024 | CNY 260M | 1.11 | 61.8% |
| 2023 | CNY 68.5M | 0.29 | 16.5% |
| 2022 | CNY 122M | 0.36 | 67.5% |
| 2021 | CNY 87.9M | 0.25 | 25.0% |
| 2020 | CNY 124M | 0.36 | 53.9% |
| 2019 | CNY 80.0M | 0.25 | 21.6% |
| 2018 | CNY 80.0M | 0.26 | 19.3% |
| 2017 | CNY 85.8M | 0.27 | 23.0% |
| 2016 | CNY 58.6M | 0.19 | 19.2% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.4:1 on Jun 20, 2024.
Who owns Shanghai Haohai Biological Tech Co
- Insiders 73.56%
- Institutions 0.40%
- Public & others 26.05%
- Shares outstanding 190M
- Free float 85.6M
Shanghai Haohai Biological Tech Co company profile
- Company name
- Shanghai Haohai Biological Tech Co
- Ticker
- 688366.SHG
- ISIN
- CNE100003NX4
- Exchange
- Shanghai Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 2,110
- Fiscal year end
- December
- Address
- Wenguang Building, Shanghai, China, 200336
- Phone
- 86 21 5229 3555
- Website
- 3healthcare.com
About Shanghai Haohai Biological Tech Co
Shanghai Haohai Biological Technology Co., Ltd. engages in the research, development, manufacture, and sale of biomedical materials in Mainland China, Europe, the United States, and internationally. The company offers ophthalmic implants, assistive devices, and medical devices; medical optical instruments, including intraocular lenses, endoscopic equipment, ophthalmic surgical instruments, and other ophthalmic medical products; hyaluronic acid and chitosan; and electronic instruments, such as semiconductors, optoelectronics, lasers, radio frequency, and ultrasonic instruments. It also engages in the research and development of biological engineering and pharmaceutical products and related technology transfer activities, consulting, and other services; research, development, production, and sales of radio frequency instruments; cell technology and biochemical product technology research and development; computer, communication, and other electronic equipment manufacturing; instrument manufacturing; manufacture and sale of biological reagents, biological agents, and biological materials; medical-grade sodium hyaluronate bio-based skincare products; intraocular lens and related products; intraocular lens injectors and materials, equipment, chemical products, and accessories for contact lenses and artificial lenses; sale of ophthalmology products; and provision of other machines and accessories. In addition, the company is involved in property management; business management consulting; non-residential real estate leasing; provision of technical services, technology promotion, development and transfer, technical consulting and exchange; wholesale of cosmetics; import and export of goods; import and export of technology; and information technology consulting services. The company was formerly known as Haohai Limited and changed its name to Shanghai Haohai Biological Technology Co., Ltd. in 2010. The company was founded in 2007 and is headquartered in Shanghai, China.
Shanghai Haohai Biological Tech Co management
5- Dr. Jianying WuGM & Chairman · born 1964
- Mr. Minjie Tang CPACFO & Executive Director · born 1975
- Ms. Yiyi ChenExecutive Director · born 1982
- Ms. Min TianJoint Company Secretary · born 1989
- Ms. Ying Tung LaiJoint Company Secretary